What is the mechanism of action of Crizanlizumab in reducing pain crises in sickle cell disease?

By William Aird

Crizanlizumab inhibits white blood cell-endothelial and platelet-endothelial interactions on blood vessel wall.

Stay Updated

If you are interested in getting the latest articles from The Blood Project, enter your name and email